A series of pentavalent phosphorus compounds containing the nitroxyl and/or aziridinyl moieties was evaluated for antitumor activity against P 388 and L 1210 lymphocytic leukemias, and compared to the clinical agent thio-TEPA (1). The compounds with the structures 5-13 were found to be active, with a T/C value greater than 125. The percent ILS was also determined. Since 1971,whenRozantsev and coworkers ^re-ported the synthesis of the spin-labeled phosphoruscontaining aziridine derivatives 2 and 3, we have been intrigued by the potential of spin labeled phosphorus compounds which could perhaps mimic pis)«3)3
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R= sitosteryl, testosteryl 13 The biological activity of derivatives of pentavalent phosphorus containing the aziridine moiety has been known for many years [1] [2] [3] [4] [5] [6] [7] . In fact, thio-TEPA (1, triethyleneimine thiophosphoramide) has been used clinically against ovarian carcinoma, Hodgkin's disease, carcinoma of the breast and other malignancies [8] .
the biological activity of clinical alkylating agents, such as, thio-TEPA (1) and at the same time contain a reporter group which might be detectable by EPR [10, 11] . The usefulness of this approach for the study of anticancer drugs in vivo was subsequently demonstrated by Dodd and coworkers [12] .
Furthermore, it was hoped that the introduction of a long lived and comparatively non-toxic radical moiety, such as the nitroxyl radical, might result in a drug which is less toxic and/or more active than the parent compound 1.
In 1973, Sosnovsky and coworkers reported [13] in this journal the preparation of nitroxyl labeled thio-TEPA analogs 4 and 5, which are more economically obtained than compounds 2 and 3 [9] . During the subsequent years, additional nitroxyland/or aziridine-containing compounds were prepared, and submitted to the National Cancer Institute for evaluation as antitumor agents. In the present communication, our interpretations of these results are presented (Table) . In addition, we have independently evaluated the clinical agent thio-TEPA (1) [14] for comparison.
The criterion of T/C, where T represents the mean survival time of the treated group, and C the mean survival time of the tumor bearing control group, is used in evaluating the chemotherapeutic potency of a given compound. A value of T/C > 125 is considered as a minimum requirement for a compound to be considered as active [14] . The percent increase life span (ILS) parameter was calculated using the formula [(T-C)/C] X 100. Clearly, the larger the value for the ILS, the more promising is the compound as an anticancer drug.
The spin-labeled derivatives 5 [13, 15, 16] 
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amine 9, appears to be inactive. As can be derived from the data, several derivatives appear to be superior to thio-TEPA with respect to the doses required for a given T/C to be obtained.
The compounds 11, 12, R = testosteryl and sitosteryl [19] , and 13 [20] likewise are active. Surprisingly, the sulfur derivative corresponding to 11, i.e. compound 14 [21] and the tocopheryl derivative 12, R = a-tocopheryl [19] were inactive, perhaps due to the instability of these compounds. .iß 0 is claimed to have a lower toxicity and a higher antitumor activity than thio-TEPA.
During the course of our studies, there appeared a report by Emanuel and coworkers [22] on the antitumor activity of compounds 2 and 15. Compound 2 was reported [22] to be less toxic than thio-TEPA (1) towards certain carcinomas. Compound 2 In summary, although the potential for antitumor agents containing aziridine rings appeared to be exhausted, promising little new insights, on the basis of our present results, a revitalization of this field seems to be possible. It is conceivable that some of the analogs of thio-TEPA discussed here will present certain advantages over the clinical agent, perhaps by having lower toxicity and/or a more favorable therapeutic index. In addition the spin labeled analogs are particularly attractive since they have high activity, possess a group easily detectable by EPR spectroscopy, and thus be utilized for metabolic studies. The full details of our investigations with the more promising compounds presented in this communication will be published in forthcoming papers [23] .
Materials and Methods
Thio-TEPA was obtained from Lederle Laboratories of Pearl River, New York, and was used without further purification. The synthesis of the derivatives listed in the Table have been previously described [13, [15] [16] [17] [18] [19] [20] [21] . The results for these derivatives were provided by the National Cancer Institute. The results for thio-TEPA were obtained in our laboratory. The detailed description of our methodology will be published in subsequent publications [23] ,
Preparation of 2-[Bis(2-chloroethyl)amino] N,N'-diimidazolyl phosphoramide (11)
A solution of bis(2-chloroethyl)phosphoramide dichloride [24] (2.55 g, 1 mmol) in benzene (50 ml) was added dropwise at 8-10 °C to a suspension of imidazole (1.36 g, 2 mmol) and triethylamine (2.5 g, 2.5 mmol) in benzene (25 ml). Following the addition, the reaction mixture was stirred at 15-20 °C for 15 h, the filtered. The filtrate was concentrated on a rotating evaporator at 20 °C/15 torr to an oil, which set to a solid on prolonged (several weeks) storage at 0°C, 3.15 g (99%), m.p. 60-62 °C (dec.).
The microanalysis was within the limits of C ± 0.2%, H ± 0.3%, N ± 0.2%.
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